New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2013
08:24 EDTSLXPSalix price target raised to $60 from $54 at Roth Capital
Roth Capital increased its price target on Salix after the company reported higher than expected Q4 EPS. The firm believes that the company's Xifaxan drug is beating expectations and it maintains a Buy rating on the shares.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SLXP

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use